AmerisourceBergen, along with nearly 100 pharmacy stakeholders, endorsed legislation that would increase transparency and accuracy in Medicare Part D prescription drug spending and reporting and effectively ban retroactive direct and indirect remuneration (DIR) fees. The Improving Transparency and Accuracy in Medicare Part D Spending Act (S.3308/H.R.5951) sponsored by Senators Shelley Moore Capito (R-WV) and John Tester (D-MT) and Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT) seeks to have price concessions like DIRs assessed at the point of sale rather than retroactively. If enacted, this legislation will create greater certainty and transparency for pharmacies and allows them to know what reimbursement is for each prescription at the point of dispensing rather than having to wait months to find out. DIR fees can go up to tens of thousands of dollars annually and knowing the true cost at point of sale will help pharmacy operations and ensure the stability of retail community pharmacy in America.
A copy of the endorsement letters can be found on the National Community Pharmacists Association’s (NCPA) website here and here.
NCPA’s accompanying press release can also be found here.
Tell your senators and representatives to cosponsor S.3308 and h.r.5951 by visiting the NCPA’s grass roots action center.